Collegium Pharmaceutical Inc (COLL) : Frazier Management scooped up 10,000 additional shares in Collegium Pharmaceutical Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 1,887,332 shares of Collegium Pharmaceutical Inc which is valued at $28.5 Million.Collegium Pharmaceutical Inc makes up approximately 17.59% of Frazier Management’s portfolio.
Other Hedge Funds, Including , Sabby Management added COLL to its portfolio by purchasing 82,100 company shares during the most recent quarter which is valued at $1.2 Million. Collegium Pharmaceutical Inc makes up approx 0.43% of Sabby Management’s portfolio. Raymond James Associates added COLL to its portfolio by purchasing 41,175 company shares during the most recent quarter which is valued at $622,154. Tfs Capital added COLL to its portfolio by purchasing 127,568 company shares during the most recent quarter which is valued at $1.9 Million. Collegium Pharmaceutical Inc makes up approx 0.28% of Tfs Capital’s portfolio.Proshare Advisors boosted its stake in COLL in the latest quarter, The investment management firm added 708 additional shares and now holds a total of 18,313 shares of Collegium Pharmaceutical Inc which is valued at $276,526.Russell Frank Co reduced its stake in COLL by selling 11,659 shares or 33.39% in the most recent quarter. The Hedge Fund company now holds 23,263 shares of COLL which is valued at $443,393.
Collegium Pharmaceutical Inc closed down -0.22 points or -1.30% at $16.67 with 1,43,174 shares getting traded on Wednesday. Post opening the session at $17.02, the shares hit an intraday low of $16.55 and an intraday high of $17.2499 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate Xtampza ER (Xtampza) is an abuse-deterrent extended-release oral formulation of oxycodone opioid medication. Xtampza has the same active ingredient as OxyContin OP which is the abuse-deterrent extended-release opioid in the United States. The Company has conducted a preclinical and clinical program for Xtampza on abuse-deterrence. These studies and clinical trials demonstrated that chewing crushing and/or dissolving Xtampza and then taking it orally or smoking snorting or injecting it did not change its drug release profile.